CompletedPhase 1NCT03009201

Ribociclib and Doxorubicin in Treating Patients With Metastatic or Advanced Soft Tissue Sarcomas That Cannot Be Removed by Surgery

Studying Angiosarcoma

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
OHSU Knight Cancer Institute
Principal Investigator
Lara E Davis
OHSU Knight Cancer Institute
Intervention
Doxorubicin Hydrochloride(drug)
Enrollment
16 enrolled
Eligibility
12 years · All sexes
Timeline
2017 – 2023

Study locations (1)

Collaborators

Novartis Pharmaceuticals · Oregon Health and Science University

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03009201 on ClinicalTrials.gov

Other trials for Angiosarcoma

Additional recruiting or active studies for the same condition.

See all trials for Angiosarcoma →

← Back to all trials